Abstract
There has been a continuing evolution of the clinical spectrum of Candida infection in nonneutropenic patients. With better understanding of the predisposing factors for fungemia in critically ill patients, interest now centers on indications for early therapy, prior to the progression of colonization to fungemia. Recent prospective trials have identified persistence of Candida species in repetitive cultures of various sites as an essential if not necessary precursor for fungemia. Treatment for patients requiring prolonged intensive-care-unit residence and demonstrating colonization with Candida is suggested, based on the frequency with which such patients progress to fungemia. The efficacy of such treatment is undocumented, and clinical trials of various regimens of polyene or azole antifungals is needed.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
